Qiu Xiaonan, Zhang Jinyue, Shi Weihong, Liu Sang, Kang Meiyun, Chu Haiyan, Wu Dongmei, Tong Na, Gong Weida, Tao Guoquan, Zhao Qinghong, Qiang Fulin, Zhu Haixia, Wu Qin, Wang Meilin, Zhang Zhengdong
Department of Environmental Genomics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China.
PLoS One. 2016 Mar 24;11(3):e0151345. doi: 10.1371/journal.pone.0151345. eCollection 2016.
In the past decades, a good deal of studies has provided the possibility of the circulating microRNAs (miRNAs) as noninvasive biomarkers for cancer diagnosis. The aim of our study was to detect the levels of circulating miRNAs in tissues and plasmas of gastric cancer (GC) patients and evaluate their diagnostic value.
Tissue samples were collected from 85 GC patients. Plasma samples were collected from 285 GC patients and 285 matched controls. Differentially expressed miRNAs were filtered with by Agilent Human miRNA Microarray and TaqMan low density array (TLDA) with pooled samples, followed by the quantitative reverse transcription polymerase chain reaction (qRT-PCR) validation. Receiver operating characteristic (ROC) curves were structured to evaluate the diagnostic accuracy of the miRNAs. The plasma level of miR-26a in GC patients of different clinical stages was compared.
Four miRNAs (miR-26a, miR-142-3p, miR-148a, and miR-195) revealed coincidentally decreased levels in tissue and plasma of the GC patients compared with controls, and ROC curves were constructed to demonstrate that miR-26a had a highest area under the ROC curve (AUC) of 0.882. Furthermore, miR-26a was stably detected in the plasma of GC patients with different clinical characteristics.
Plasma miR-26a may provide a novel and stable marker of gastric cancer.
在过去几十年中，大量研究为循环微小RNA（miRNA）作为癌症诊断的非侵入性生物标志物提供了可能性。我们研究的目的是检测胃癌（GC）患者组织和血浆中循环miRNA的水平，并评估其诊断价值。
收集85例GC患者的组织样本。收集285例GC患者和285例匹配对照的血浆样本。通过安捷伦人类miRNA微阵列和TaqMan低密度阵列（TLDA）对混合样本进行差异表达miRNA筛选，随后进行定量逆转录聚合酶链反应（qRT-PCR）验证。构建受试者工作特征（ROC）曲线以评估miRNA的诊断准确性。比较不同临床分期GC患者血浆中miR-26a的水平。
与对照组相比，四种miRNA（miR-26a、miR-142-3p、miR-148a和miR-195）在GC患者的组织和血浆中水平均同时降低，构建ROC曲线显示miR-26a的ROC曲线下面积（AUC）最高，为0.882。此外，在具有不同临床特征的GC患者血浆中稳定检测到miR-26a。
血浆miR-26a可能为胃癌提供一种新的稳定标志物。
